Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Fifteen of the biotechnology company’s products delivered at least double-digit sales growth in the second quarter.

Amgen (NASDAQ:AMGN) surpasses Q2 earnings and revenue expectations with a 9.4% revenue growth. Read more here.

Amgen Inc (NASDAQ:AMGN) shares were slightly lower in premarket trading despite posting better-than-expected quarterly profit ...

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...

Biotech company Amgen (NASDAQ:AMGN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 9.4 ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen (AMGN) to announce Q2 earnings with expected 6% growth in EPS & revenue. Key acquisitions bolster rare disease pipeline ...

Amgen’s diversified portfolio strategy continues to hinge on a balance between high-margin legacy biologics, expanding biosimilar offerings, and innovative pipeline investments. Repatha and BLINCYTO ...

Analysts estimate that Amgen will report an earnings per share (EPS) of $5.26. The announcement from Amgen is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

President Donald Trump just sent letters to heads of 17 major pharmaceutical companies pushing them to drop drug prices in ...